ClinicalTrials.gg
CompletedNCT04586985Updated Dec 12, 2022

Safety, Tolerability and Pharmacokinetics of FTX-6058

A Phase 1 interventional study of FTX-6058/placebo oral capsule(s) and FTX-6058/placebo oral capsule(s) in Healthy Adult Subjects and Sickle Cell Disease, sponsored by Fulcrum Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-12.

Sponsored by Fulcrum Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
101st of 559
109 · median 31
Started
2020
with 46 others
Phase 1
98 of 733
13 open now
Registered
520th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 101st largest by enrollment of the 559 interventional ones that give a count, is one of 47 that started in 2020, is one of 98 in phase 1, and was the 520th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This is a study to evaluate the safety, tolerability and pharmacokinetics of FTX-6058 in healthy adult subjects and adult subjects with sickle cell disease (SCD).

Read the detailed description

This study is a Phase 1 randomized, double-blind, placebo-controlled, single- and multiple-dose study evaluating safety, tolerability, and pharmacokinetics, with an open-label initial food effect and CYP3A drug-drug interaction study, of FTX-6058 in healthy adult subjects and a randomized, double-blind, placebo-controlled, multiple-dose study in adult subjects with sickle cell disease (SCD).

This study will comprise 5 parts and will be conducted in healthy adult subjects and adult subjects with sickle cell disease (SCD) (Part E only).

Part A will be a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in up to 8 cohorts of healthy adult subjects. Part B will be a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study in up to 6 cohorts of healthy adult subjects dosed once daily for 14 days. Part C will be an open-label pilot food effect study in healthy adult subjects randomized to take FTX-6058 with and without a high-fat meal, and Part D will be an open-label study to evaluate the potential of FTX-6058 to induce CYP3A (using midazolam) in healthy adult subjects. Part E will be a randomized, double-blind, placebo-controlled, multiple dose study in adult subjects with sickle cell disease (SCD). Subjects in Part E may enroll into Study 6058-SCD-101 (NCT 05169580) Part A (6 mg cohort) at the Day 15 visit; subjects that enroll into 6058-SCD-101 will not need to undergo the Safety Follow-up visit.

The primary endpoint of the study is to evaluate the safety and tolerability of FTX-6058 in healthy adult subjects and adult subjects with sickle cell disease as measured by the frequency of adverse events. Secondary endpoints include evaluation of the pharmacokinetics of single dose and multiple dose FTX-6058 in healthy adult subjects, pharmacokinetics of multiple dose FTX-6058 in adult subjects with sickle cell disease, evaluation of the potential effect of food on FTX-6058 and evaluation of the potential for CYP3A induction by FTX-6058 in healthy adult subjects.

03

Conditions studied

  • Healthy Adult Subjects
  • Sickle Cell Disease

Browse trials for

Keywords

  • Healthy Adult Subjects
  • Sickle Cell Disease
  • Sickle Cell Anemia
  • Sickle Cell Disorder
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Healthy Subjects

  1. Healthy male / female subjects, 18 to 55 years of age, inclusive at screening.
  2. Good health, based upon the opinion of the investigator and the results of medical history, physical examination, vital signs, , and laboratory profiles of both blood and urine at screening.
  3. (BMI) between 18 and 32 kg/m², inclusive at screening, and with a minimum weight of 50 kg.
  4. Willingness of men and women of to agree to use two effective means of throughout study participation until 90 days after dose administration.
  5. Signed and dated written .
  6. Willing and able to comply with all study procedures.
  7. Females with hematocrit >35% and \<45% or >11.7/dL and \<15.5/dL and males with hematocrit >38.5% and \<50% or hemoglobin >13.2/dL and \<17.1/dL.

Exclusion Criteria: Healthy Subjects

  1. History of any illness or any clinical condition that, in the opinion of the investigator/sub-investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. This may include, but is not limited to, history or presence of gastrointestinal conditions including Crohn's disease, ulcerative colitis, frequent episodes of diarrhea, or irritable bowel syndrome; history of relevant drug or food allergies; history of cardiovascular or central nervous system disease; history or presence of pathology; clinically significant history of mental disease; concurrent active ; and history of cancer, except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ (all 3 with no recurrence for the last 5 years).
  2. History of febrile illness within 1 week prior to the baseline visit.
  3. Acute or chronic history of liver disease or current ≥ 2 × or total >1.5 × ULN at screening (Note: Subjects with Gilbert's syndrome are permitted to enroll in the trial).
  4. Known renal impairment (defined as of \<60 mL/min/1.73 m²).
  5. Positive screen for surface antigen (HBsAg), virus (HCV) antibody, or antibodies against human immunodeficiency viruses 1 and 2 (HIV1/HIV2 Abs) at screening.
  6. Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy, or other gastrointestinal tract surgery, except appendectomy).
  7. Standard 12 lead ECG demonstrating >450 msec for male subjects and QTcF >470 msec for female subjects at screening. If QTcF exceeds 450 msec for males or 470 msec for females, the ECG will be repeated 2 more times, and the average of the 3 QTcF values will be used to determine the subject's eligibility.
  8. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) or history or evidence of abnormal ECGs that, in the opinion of the investigator or medical monitor, would preclude the subject's participation in the study.
  9. Blood or blood product (e.g., plasma/serum) donation (of approximately 1 pint [500 mL] or more) or any significant loss of blood within 8 weeks prior to screening or intention to donate blood or blood products during the study as determined by the investigator.
  10. History of abuse of addictive substances such as drug abuse, or regular user of sedatives, hypnotics, tranquilizers, or any other addictive agent within 6 months prior to screening.
  11. History of regular alcohol consumption within 6 months prior to screening defined as: (a) An average weekly intake of greater than 21 units. One unit is equivalent to a 285 mL glass of full-strength beer or 425 mL of light beer or 1 (30 mL) measure of spirits or 1 glass (100 mL) of wine.
  12. History of demonstrating an excess in xanthine or caffeine consumption (more than 8 cups of coffee or equivalent per day).
  13. Use of another product within 30 days or 5 half-lives (whichever is longer), or according to local regulations, or currently participating in a prospective study with an investigational product or medical device.
  14. Use of any medication (prescription or over-the-counter [OTC]) within 14 days of study drug administration, or use of herbal supplements, dietary supplements or multivitamins within 7 days of study drug administration or less than 5 half-lives (whichever is longer), with the exception of paracetamol (up to 3 g/day). Other exceptions will only be made if the rationale is clearly documented by the investigator (a) Note: Any vaccination, including COVID-19 vaccine, cannot be administered within 14 days prior to initial dose of study drug until the end of study participation.
  15. History of sensitivity to the study drug or placebo, or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
  16. Female subject who is pregnant, trying to become pregnant, or is breastfeeding or male subject whose partner is pregnant, trying to become pregnant, or is breastfeeding.
  17. Subject is mentally or legally incapacitated.
  18. Abnormal laboratory results indicative of any significant medical disease that, in the opinion of the investigator, would preclude the subject's participation in the study at screening or prior to first dose.
  19. Subject, or close relative of the subject, is the investigator or a sub-investigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study at that site.
  20. Positive test for drugs of abuse at screening or baseline.
  21. Positive test for COVID-19 prior to admission to the study site, as required per local regulations.
  22. Subject smokes cigarettes (or equivalent) and/or has used nicotine-based products within 3 months prior to screening. (a) Note: Cotinine test is not required per protocol but may be performed at the discretion of the Investigator to confirm non-smoker status.
  23. Consumption of any alcohol within the 48-hour period prior to study drug administration.
  24. Plans for hospitalization, surgery, or other major procedures during the study duration or between screening and baseline.
  25. Part D Only: Any to the use of midazolam.

Inclusion Criteria: Sickle Cell Disease Subjects

  1. Subject is 18 to 55 years of age at the time informed consent is obtained. Subject has provided consent before any study-specific procedures are performed and is willing and able to comply with the study procedures and restrictions.
  2. Body mass index (BMI) between 18 and 32 kg/m², inclusive at screening, and with a minimum weight of 50 kg
  3. Willingness of men and women of reproductive potential must agree to use 2 effective means of contraception throughout study participation until 90 days after dose administration.
  4. Signed and dated written informed consent.
  5. Confirmed Sickle Cell Disease (SCD) at the time of screening (SS and S/β⁰) by high performance liquid chromatography (HPLC).
  6. HbF ≤20% of total hemoglobin (Hb) at screening by HPLC
  7. SCD characterized by both of the following: (a) Total hemoglobin between 5.5 and 10.5 g/dL at screening; (b) 0-6 vaso-occlusive crisis (VOC) episodes over the 12 months prior to screening (VOC is defined as pain crises (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso- occlusion and which requires therapy with oral or parenteral opioids or parenteral NSAIDs) as well as other complicated crises, such as acute chest syndrome (ACS), priapism, and hepatic or splenic sequestration.).
  8. Subject must meet both of the following laboratory values at screening: (a) ≥1.5/ × 10⁹/L; (b) ≥80 × 10⁹/L
  9. Absolute reticulocyte count at screening higher than 100 × 10⁹/L

Exclusion Criteria: Sickle Cell Disease Subjects

  1. Major surgery, hospitalization, infection, significant bleeding, cerebrovascular accident or seizure, or transfusion within 14 days prior to study enrollment through conclusion of study follow-up period; elective surgery planned for the time period of the trial.
  2. Sickle cell complication requiring hospitalization in the past 14 days or > 6 total VOCs over the past 12 months requiring hospitalization.
  3. Use of opioids and/or opiates (unless used for chronic pain management), anticoagulants, or medications that induce or inhibit within 14 days prior to starting study drug or anticipated need for any of these agents during the study. (Pain meds for chronic pain management or VOC events occurring during the study may be administered at the discretion of the investigator.)
  4. Use of voxelotor or hydroxyurea within 60 days prior to starting study drug.
  5. Participation in any other investigative treatment studies within the past 60 days.
  6. History of bone marrow transplant or human stem cell transplant or gene therapies.
  7. Vaccination (including against COVID-19) in the previous 14 days.
  8. Positive test for COVID-19 prior to admission to the study site, as required per local regulations.
  9. Significant abnormalities in hepatic biochemical tests that, in the opinion of the investigator, are outside the typical range seen with SCD. Potential subjects are to be excluded if alanine aminotransferase (ALT) or aspartate transaminase (AST) ≥3× ULN or albumin \<2.0 mg/dL or direct (conjugated) bilirubin ≥1.5 mg/dL or /international normalized ratio > 1.5 ULN.
  10. Subjects with end stage renal disease defined as glomerular filtration rate \<10 mL/min/1.73m², using Schwartz formula or serum creatinine >1.2 mg/dL and calculated \<30 mL/min. Subjects on dialysis are excluded.
  11. Subjects with abnormal laboratory results indicative of any significant medical disease that, in the opinion of the investigator, would preclude the subject's participation in the study or potentially obscure the interpretation of the scheduled assessments. Screening laboratory assessments may be repeated up to twice at the discretion of the investigator.
  12. Subjects being treated with antiretroviral agents (such as didanosine and stavudine).
  13. Infection with (HIV), hepatitis B, or hepatitis C such that subjects are currently on therapy or will be placed on therapy during the trial
  14. Subjects receiving regularly scheduled transfusions to reduce levels of HbS.
  15. Clinically diagnosed substance use disorder for alcohol or other illicit drugs of abuse. Positive urine drug screen at screening or on day of admission for substances other than marijuana or prescribed opioids/opiates for chronic pain management is exclusionary.
  16. Pregnant or lactating female; or female of childbearing age unable or unwilling to comply with birth control or abstinence during the course of the study.
  17. Febrile illness in the 7 days prior to baseline visit.
  18. Subject is investigative site personnel or member of their immediate family (spouse, parent, child or sibling whether biological or legally adopted).
  19. Heart rate corrected QT interval-Frederica's method (QTcF) >450 msec male and >470 msec female.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose (SAD) cohorts in Healthy Subjects (Part A)

    Subjects will be randomized to receive a single dose of FTX-6058 or placebo. Cohorts 1 and 2 will enroll 5 subjects per cohort randomized 3:2. Cohorts 3-8 will enroll 7 subjects per cohort randomized 5:2. Planned doses are 2 mg (Cohort 1), 4 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), 40 mg (Cohort 6), 60 mg (Cohort 7), and 90 mg (Cohort 8).

    Drug: FTX-6058/placebo oral capsule(s)

  • Experimental
    Multiple Ascending Dose (MAD) cohorts in Healthy Subjects (Part B)

    Subjects will be randomized 3:1 to receive once daily FTX-6058 or placebo by mouth for 14 days. Up to 6 cohorts of 8 subjects per cohort will be enrolled. Planned doses are 2 mg (Cohort 1), 6 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), and 40 mg (Cohort 6).

    Drug: FTX-6058/placebo oral capsule(s)

  • Experimental
    Pilot Food Effect Cohort in Healthy Subjects (Part C)

    Ten subjects will be randomized to receive a single 20 mg dose of FTX-6058 with and without a high-fat meal with a washout period of 4 days.

    Drug: FTX-6058 - Two Dosing Periods

  • Experimental
    Potential for CYP3A Induction in Healthy Subjects (Part D)

    Sixteen subjects will receive 3 mg Midazolam once by mouth on Day 1. On Days 3-12, subjects will receive FTX-6058 by mouth once daily. On Day 12, a second dose of 3 mg Midazolam will be given once by mouth. The dose of FTX-6058 will be the highest tolerated dose from Part B.

    Drug: FTX-6058 / Midazolam Syrup

  • Experimental
    Multiple Dose Cohort in Sickle Cell Disease Subjects (Part E)

    Subjects will be randomized 3:1 to receive FTX-6058 or placebo once daily by mouth for 14 days. Up to 8 subjects will be enrolled. The planned dose is 6mg.

    Drug: FTX-6058/placebo oral capsule(s)

Interventions

  • DrugFTX-6058/placebo oral capsule(s)

    Subjects will receive FTX-6058 or matching placebo.

  • DrugFTX-6058/placebo oral capsule(s)

    Subjects will receive FTX-6058 or matching placebo.

  • Subjects will receive FTX-6058

  • DrugFTX-6058 / Midazolam Syrup

    Subjects will receive FTX-6058 and midazolam syrup

  • DrugFTX-6058/placebo oral capsule(s)

    Subjects will receive FTX-6058 or matching placebo.

06

What researchers measure

Primary outcomes

  1. Treatment-Emergent Adverse Events

    To evaluate the safety and tolerability of FTX-6058 in healthy adult subjects and adult subjects with sickle cell disease based on the frequency of adverse events (AEs), frequency of serious adverse events (SAEs), and clinically significant laboratory test results, electrocardiograms (ECGs), and vital signs.

    Time frame: Up to approximately 4 weeks of monitoring

Secondary outcomes

  1. Plasma Concentrations of FTX-6058

    Blood samples will be collected to measure the plasma concentration of FTX-6058 at specified timepoints by liquid chromatography with tandem mass spectrometry.

    Time frame: Study Part A: Days 1, 2, 3 and 4

  2. Plasma Concentrations of FTX-6058

    Blood samples will be collected to measure the plasma concentration of FTX-6058 at specified timepoints by liquid chromatography with tandem mass spectrometry

    Time frame: Study Part B: Days 1, 2, 7, 8-10, 11-14 and 15

  3. Plasma Concentrations of FTX-6058

    Blood samples will be collected to measure the plasma concentration of FTX-6058 at specified timepoints by liquid chromatography with tandem mass spectrometry.

    Time frame: Study Part C: Days 1-4

  4. Plasma Concentrations of Midazolam

    Blood samples will be collected to measure the plasma concentration of Midazolam at specified timepoints by liquid chromatography with tandem mass spectrometry

    Time frame: Study Part D: Days 1, 2, 12 and 13

  5. Plasma Concentrations of for 1-OH-Midazolam

    Blood samples will be collected to measure the plasma concentration of 1-OH-Midazolam at specified timepoints by liquid chromatography with tandem mass spectrometry.

    Time frame: Study Part D: Days 1, 2, 12 and 13

  6. Plasma Concentrations of FTX-6058

    Blood samples will be collected to measure the plasma concentration of FTX-6058 at specified timepoints by liquid chromatography with tandem mass spectrometry.

    Time frame: Study Part E: Days 1, 7 and 14

Other outcomes

  1. Predictive Model of the Relationship between FTX-6058 Concentration and QTc Intervals

    A model of the relationship between time-match FTX-6058 plasma concentrations and QTc intervals may be developed and will include simulations to predict potential QT risk.

    Time frame: Study Part A: Days 1 and 2

  2. Predictive Model of the Relationship between FTX-6058 Concentration and QTc Intervals

    A model of the relationship between time-match FTX-6058 plasma concentrations and QTc intervals may be developed and will include simulations to predict potential QT risk.

    Time frame: Study Part B: Days 1, 2, and 7-15

  3. Target Engagement of FTX-6058

    Change from baseline in H3K27me3/Total Histone H3 ratio in circulating monocytes will be evaluated by fluorescence-activated cell sorting (FACS).

    Time frame: Study Part B: Days -1, 7, 11-14 and 7-10 days after last dose of study drug

  4. Target Engagement of FTX-6058

    Change from baseline in H3K27me3/Total Histone H3 ratio in circulating monocytes will be evaluated by fluorescence- activated cell sorting (FACS).

    Time frame: Study Part E : Days -1, 7,14 and and 7-10 days after last dose of study drug

07

Study locations

2 sites
  • Atlanta Center for Medical Research - Sickle Cell Subjects Only
    Atlanta, Georgia 30331, United States
  • Altasciences Clinical Kansas, Inc. - Healthy Adults Subjects Only
    Overland Park, Kansas 66212, United States
08

References and documents

Publications

  • Ngo DA, Aygun B, Akinsheye I, Hankins JS, Bhan I, Luo HY, Steinberg MH, Chui DH. Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol. 2012 Jan;156(2):259-64. doi: 10.1111/j.1365-2141.2011.08916.x. Epub 2011 Oct 24. PubMed 22017641 ↗
  • Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017 Apr 20;376(16):1561-1573. doi: 10.1056/NEJMra1510865. No abstract available. PubMed 28423290 ↗
  • Sankaran VG, Orkin SH. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med. 2013 Jan 1;3(1):a011643. doi: 10.1101/cshperspect.a011643. PubMed 23209159 ↗
  • Saraf SL, Molokie RE, Nouraie M, Sable CA, Luchtman-Jones L, Ensing GJ, Campbell AD, Rana SR, Niu XM, Machado RF, Gladwin MT, Gordeuk VR. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev. 2014 Mar;15(1):4-12. doi: 10.1016/j.prrv.2013.11.003. Epub 2013 Nov 15. PubMed 24361300 ↗
  • Steinberg MH, Chui DH, Dover GJ, Sebastiani P, Alsultan A. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 2014 Jan 23;123(4):481-5. doi: 10.1182/blood-2013-09-528067. Epub 2013 Nov 12. PubMed 24222332 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Nov 2022, 24 months.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 24 months is close to that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2020
First posted
Oct 14, 2020
StartActual
Oct 26, 2020
Primary completionActual
Nov 15, 2022
CompletionActual
Nov 15, 2022
Last update
Dec 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04586985
Lead sponsor
Fulcrum Therapeutics
Responsible party
Sponsor
First posted
Oct 14, 2020
Start date
Oct 26, 2020
Primary completion
Nov 15, 2022
Completion
Nov 15, 2022
Last update
Dec 12, 2022

Study contacts

John Ziegler, MD, FASA
study director · Fulcrum Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pociredir

Start the discussion